全文获取类型
收费全文 | 8609篇 |
免费 | 848篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 107篇 |
儿科学 | 218篇 |
妇产科学 | 268篇 |
基础医学 | 1164篇 |
口腔科学 | 124篇 |
临床医学 | 784篇 |
内科学 | 1970篇 |
皮肤病学 | 130篇 |
神经病学 | 883篇 |
特种医学 | 279篇 |
外科学 | 1170篇 |
综合类 | 263篇 |
一般理论 | 6篇 |
预防医学 | 561篇 |
眼科学 | 194篇 |
药学 | 537篇 |
中国医学 | 37篇 |
肿瘤学 | 806篇 |
出版年
2023年 | 66篇 |
2022年 | 107篇 |
2021年 | 244篇 |
2020年 | 185篇 |
2019年 | 251篇 |
2018年 | 245篇 |
2017年 | 174篇 |
2016年 | 201篇 |
2015年 | 256篇 |
2014年 | 323篇 |
2013年 | 386篇 |
2012年 | 554篇 |
2011年 | 564篇 |
2010年 | 310篇 |
2009年 | 278篇 |
2008年 | 467篇 |
2007年 | 449篇 |
2006年 | 444篇 |
2005年 | 392篇 |
2004年 | 376篇 |
2003年 | 379篇 |
2002年 | 310篇 |
2001年 | 242篇 |
2000年 | 231篇 |
1999年 | 203篇 |
1998年 | 94篇 |
1997年 | 63篇 |
1996年 | 63篇 |
1995年 | 62篇 |
1994年 | 54篇 |
1993年 | 49篇 |
1992年 | 146篇 |
1991年 | 135篇 |
1990年 | 128篇 |
1989年 | 112篇 |
1988年 | 99篇 |
1987年 | 100篇 |
1986年 | 84篇 |
1985年 | 95篇 |
1984年 | 69篇 |
1983年 | 47篇 |
1982年 | 40篇 |
1981年 | 37篇 |
1980年 | 29篇 |
1979年 | 38篇 |
1978年 | 36篇 |
1977年 | 38篇 |
1976年 | 25篇 |
1975年 | 33篇 |
1974年 | 29篇 |
排序方式: 共有9501条查询结果,搜索用时 15 毫秒
131.
A L Hamilton J P Eder A C Pavlick J W Clark L Liebes R Garcia-Carbonero A Chachoua D P Ryan V Soma K Farrell N Kinchla J Boyden H Yee A Zeleniuch-Jacquotte J Wright P Elliott J Adams F M Muggia 《Journal of clinical oncology》2005,23(25):6107-6116
PURPOSE: We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to determine the recommended phase II dose and toxicity profile, and the extent of 20S proteasome inhibition obtained. PATIENTS AND METHODS: Patients with solid tumors or lymphomas were treated with bortezomib at 0.25 to 1.9 mg/m2 on D1 and D4, every 2 weeks. 20S proteasome levels in blood were assayed at baseline and at 1, 4, and 24 hours postdose in cycle 1. RESULTS: On this D1 and D4 every 2 weeks' schedule, dose-limiting toxicity (DLT) was evident at the 1.75 and 1.9 mg/m2 dose levels, most commonly in patients receiving individual total doses > or = 3.0 mg. The main DLT was peripheral neuropathy evident at the higher doses and in patients previously exposed to neurotoxic agents. Other DLTs included diarrhea and fatigue; grade 3 thrombocytopenia was also noted. Reversible inhibition of 20S proteasome activity was dose dependent and best fit a total dose (mg) per fraction rather than mg/m2; 70% of baseline activity was inhibited by a dose of 3.0 to 3.5 mg given on D1 and on D4 every other week. Antitumor effects short of confirmed partial responses were observed in patients with melanoma, non-small-cell lung cancer, and renal cell carcinoma. CONCLUSION: Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not exceeding 3.0 mg (equivalent to 1.75 mg/m2), repeated on D1 and D4 every other week. This dose correlates with 70% inhibition of 20S proteasome activity. DLTs include neuropathy, fatigue, and diarrhea. 相似文献
132.
Francis Giles Srdan Verstovsek Deborah Thomas Stanton Gerson Jorge Cortes Stefan Faderl Alessandra Ferrajoli Farhad Ravandi Steven Kornblau Guillermo Garcia-Manero Elias Jabbour Susan O'Brien Verena Karsten Ann Cahill Karen Yee Maher Albitar Mario Sznol Hagop Kantarjian 《Clinical cancer research》2005,11(21):7817-7824
PURPOSE: Cloretazine (VNP40101M) is a novel sulfonylhydrazine alkylating agent with significant antileukemia activity. A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease. DESIGN: Ara-C was given i.v. at a fixed dose of 1.5 gm/m(2)/d by continuous infusion for 4 days (patients ages <65 years at time of diagnosis) or 3 days (patients ages > or =65 years). Cloretazine was given i.v. over 15 to 60 minutes on day 2 at a starting dose of 200 mg/m(2), with escalation in 100 mg/m(2) increments in cohorts of three to six patients until a maximum tolerated dose was established. The DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT) was measured at baseline. RESULTS: Forty patients, including 32 with acute myeloid leukemia, received 47 courses of treatment. Complete responses were seen at cloretazine dose levels of > or =400 mg/m(2) in 10 of 37 (27%) evaluable patients, and in this patient subset, AGT activity was significantly lower in patients that responded to treatment than in patients who did not (P < or = 0.027). Dose-limiting toxicities (gastrointestinal and myelosuppression) were seen with 500 and 600 mg/m(2) of cloretazine combined with the 4-day ara-C schedule but not seen with the 3-day schedule. CONCLUSION: The recommended cloretazine dose schedule for future studies is 600 mg/m(2) combined with 1.5 gm/m(2)/d continuous infusion of ara-C for 3 days. The cloretazine and ara-C regimen has significant antileukemic activity. AGT activity may be a predictor of response to cloretazine. 相似文献
133.
134.
135.
136.
137.
Samantha Yee BSW MSW Kaajal Abrol MD Melanie McDonald BA MSW Madeline Tonelli RN BSCN MED Kimberly E. Liu MD MSL 《Journal of psychosocial oncology》2013,31(3):331-346
A total of 41 questionnaires were returned from 64 respondents who consented to receive a questionnaire through the mail. Almost all valued the opportunity to receive consultation to address their fertility concerns and discuss fertility preservation options. Psychological stress, time pressure, and costs were identified as main factors affecting respondents’ decision to proceed with in-vitro fertilization to cryopreserve oocytes or embryos. About one third indicated that the discussion of fertility matters was initiated by themselves, their friends, and families rather than their health care providers. The findings have identified several major barriers encountered by female cancer patients when seeking fertility preservation services. 相似文献
138.
T. Liu M. David M. Batstone J. Clark T.-H. Low D. Goldstein A. Hope A. Hosni B. Chua 《International journal of oral and maxillofacial surgery》2021,50(2):143-150
The effectiveness of postoperative radiotherapy (PORT) in improving outcomes remains debatable for oral squamous cell carcinoma (OSCC) patients with pathological intermediate-risk factors (IRFs) after surgery. A retrospective analysis was conducted on 432 intermediate-risk OSCC patients defined by histological reporting of close margin (<5 mm), early nodal disease (pN1), depth of invasion/tumour thickness ≥5 mm, perineural invasion, and/or lymphovascular invasion. Outcomes measured were disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). PORT was associated with an improvement in 5-year DFS on univariable analysis (80% vs 71%; P = 0.044), but this did not remain significant on multivariable analysis. PORT was not associated with differences in DSS or OS. The surgical salvage rate was similar in the PORT and surgery-only groups (41% vs 47%; P = 0.972). Perineural invasion was found to be an independent predictor of inferior DSS (hazard ratio (HR) 2.19), DFS (HR 1.89), and OS (HR 1.97). Significantly worse outcomes were observed for patients with ≥4 concurrent IRFs. The application of PORT was associated with lower rates of recurrence, but the benefit was less apparent on mortality. Patients with perineural invasion and multiple concurrent IRFs were found to be at greatest risk, representing a subset of intermediate-risk OSCC patients who may benefit from PORT. 相似文献
139.
140.
Scott Harpin Jillian Davis Hana Low Christine Gilroy 《Journal of community health nursing》2016,33(2):90-97
The purpose of this study was to investigate homeless youth mobile phone and social media use, to plan health promotion efforts. Nearly half (46.7%) of runaway/homeless youth in this sample (n = 181) owned a mobile phone and a majority of those devices were smart phones. Ownership did not vary significantly by shelter location, though regular use of Facebook was more prevalent among those in housing programs or camping, than those living on the streets. Over 90% of youth in the sample reported using Facebook. Such media use might facilitate parent, family, and health provider communications with homeless youth. 相似文献